



1 **Supplementary Materials**


2

3 **Chemistry**

4 **Syntheses**

5 *General procedure for the synthesis of N¹-aryl-pyrazole derivatives*

6



7

8

9

Scheme S1. Reagents and conditions: a) EtOH, H⁺_{cat.}, Δ, 3h; b) LiOH 1N, EtOH, 0 °C to r.t., 5h; c) 4-NH₂PhCO₂Et, EDCl,

10

HOBt, CH₂Cl₂, 0 °C to r.t., overnight; d) LiOH 1N, THF, 0 °C to r.t., 6h; e) TBDMSiO-NH₂, EDCl, CH₂Cl₂, 0 °C to r.t.,


11

overnight; f) TFA, CH₂Cl₂, 0 °C, 5h.

12

13 *Formation of the N¹-phenyl-pyrazole scaffold*


14



15

16 **Reagents and conditions:** EtOH, H⁺_{cat.}, Δ, 3h.

17

18 **11a:** Ethyl 3-methyl-1-phenyl-1H-pyrazole-5-carboxylate

19


20

21 Mol. Wt.: 230.26


22 ^1H NMR (500 MHz, CDCl_3) : δ ppm 7.42–7.38 (m, 5H, Ar), 6.80 (s, 1H, H-4), 4.20 (q, 2H, $J = 7.1$ Hz, $-\text{CH}_2\text{CH}_3$), 2.35 (s,23 3H, Pyr- CH_3), 1.21 (t, 3H, $J = 7.1$ Hz, $-\text{CH}_2\text{CH}_3$). $R_f = 0.74$ (TLC: EP/EtOAc 8:2). Reddish-brown oil. Yield: 245 mg (42%).

24

25



26

27 **11b:** Ethyl 5-methyl-1-phenyl-1H-pyrazole-3-carboxylate

28


29

30 Mol. Wt.: 230.26

31 ^1H NMR (500 MHz, CDCl_3): δ ppm 7.45–7.39 (m, 5H, Ar), 6.72 (s, 1H, H-4), 4.39 (q, 2H, , $J = 7.1$ Hz, $-\text{CH}_2\text{CH}_3$), 2.31 (s,32 3H, Pyr- CH_3), 1.37 (t, 3H, $J = 7.1$ Hz, $-\text{CH}_2\text{CH}_3$). $R_f = 0.48$ (TLC: EP/EtOAc 8:2). Reddish-brown oil. Yield: 205 mg (35%).


33

34



35


36 NOESY 11a:




37

38


39



40 NOESY 11b:




41
42
43



44 **Hydrolysis of the ester moiety of the N¹-phenyl-pyrazole scaffold**


45



46

47 **Reagents and conditions:** LiOH 1 N, EtOH, 0 °C to rt, 5h.

48

49 **14a: 3-Methyl-1-phenyl-1H-pyrazole-5-carboxylic acid**


50

51 Mol. Wt.: 202.21

52 ¹H NMR (500 MHz, CDCl₃): δ ppm 7.37–7.34 (m, 5H, Ar), 6.82 (s, 1H, H-4), 2.31 (s, 3H, CH₃). M.p. = 145–149 °C; R_f =

53 0.15 (TLC: 2% HCOOH in EP/EtOAc 1:1). Yellow-brownish powder. Yield: 202 mg (94%).

54



55

56 **Reagents and conditions:** LiOH 1 N, EtOH, 0 °C to rt, 5h.

57

58 **14b: 5-Methyl-1-phenyl-1H-pyrazole-3-carboxylic acid**

59

60

61 Mol. Wt.: 202.21


62 ¹H NMR (500 MHz, CDCl₃): δ ppm 7.45–7.41 (m, 5H, Ar), 6.74 (s, 1H, H-4), 2.31 (s, 3H, CH₃). M.p. = 41–43 °C; R_f = 0.18

63 (TLC: 2% HCOOH in EP/EtOAc 1:1). Needle-shaped whitish crystals. Yield: 167 mg (93%).

64

65 Coupling reaction between *N*¹-phenyl-pyrazole scaffold (CAP) and cinnamoyl linker

66




67

68 Reagents and conditions: EDCI (1.5 eq), HOBt (1.5), CH₂Cl₂, 0 °C, overnight.

69

70 **17a:** (E)-Ethyl 3-(4-(3-methyl-1-phenyl-1H-pyrazole-5-carboxamido)phenyl)acrylate

71



72


73

74 Mol. Wt.: 375.42

75 ¹H NMR (500 MHz, CDCl₃): δ ppm 7.86 (bs, 1H, NH), 7.60 (d, *J* = 16.2 Hz, 1H, Ar-CH=), 7.46-7.41 (m, 9H, Ar), 6.67 (s,
76 1H, H-4), 6.34 (d, 1H, *J* = 16.2 Hz, =CHCO₂Et), 4.24 (q, *J* = 6.9 Hz, 2H, -CH₂CH₃), 2.35 (s, 3H, Pyr-CH₃), 1.32 (t, *J* = 6.9 Hz,
77 -CH₂CH₃).

78 ¹³C NMR (125 MHz, CDCl₃): δ ppm 167.0 (-COOEt), 157.4 (-CONH), 149.1 (C5), 143.6 (ArCH=), 139.4, 138.9, 137.3, 130.8,
79 129.1, 128.9, 128.6, 125.2, 119.9, 117.5 (C4), 109.3 (=CHCO), 60.5 (CH₂), 14.3 (-CH₂CH₃), 13.3 (Pyr-CH₃). *R*_f = 0.53 (TLC:
80 EP/EtOAc 7:3); yellow-brownish powder. M.p. = 98–102 °C. Yield: 251 mg (67%).

81




82

83 Reagents and conditions: EDCI (1.5 eq), HOBt (1.5), CH₂Cl₂, 0 °C, overnight.

84

85 **17b:** (E)-Ethyl 3-(4-(5-methyl-1-phenyl-1H-pyrazole-3-carboxamido)phenyl)acrylate

86



87

88

89 Mol. Wt.: 375.42


90 ^1H NMR (500 MHz, CDCl_3): δ ppm 8.88 (bs, 1H, NH), 7.72 (d, 2H, $J = 8.4$ Hz, ArH), 7.64 (d, $J = 16.3$ Hz, 1H, Ar-CH=),91 7.65-7.46 (m, 7H, Ar), 6.82 (s, 1H, H-4), 6.36 (d, 1H, $J = 16.3$ Hz, =CHCO₂Et), 4.24 (q, $J = 7.1$ Hz, 2H, -CH₂CH₃), 2.35 (s,92 3H, Pyr-CH₃), 1.32 (t, $J = 7.1$ Hz, -CH₂CH₃).93 ^{13}C NMR (125 MHz, CDCl_3): δ ppm 167.2 (-COOEt), 159.9 (-CONH), 146.5 (C3), 144.0 (ArCH=), 141.6, 139.8, 139.0, 130.0,94 129.4, 129.0, 128.8, 125.2, 119.6, 116.9 (C4), 107.6 (=CHCO), 60.4 (CH₂), 14.3 (-CH₂CH₃), 12.4 (Pyr-CH₃). $R_f = 0.57$ (TLC:

95 EP/EtOAc 7:3); yellowish powder. M.p. = 105–109 °C. Yield: 195 mg (63%).

96

97 **Hydrolysis of the intermediate CAP-linker**

98




99

100 **Reagents and conditions:** LiOH 1 N, THF, 0 °C to rt, 6h.

101

102 **20a:** (E)-3-(4-(3-Methyl-1-phenyl-1H-pyrazole-5-carboxamido)phenyl)acrylic acid

103



104

105


106 Mol. Wt.: 347.37

107 ^1H NMR (500 MHz, CDCl_3): δ ppm 7.70 (d, $J = 16.3$ Hz, 1H, Ar-CH=), 7.52-7.44 (m, 10H, 9ArH + NH), 6.71 (s, 1H, H-4),108 6.37 (d, 1H, $J = 16.3$ Hz, =CHCO₂H), 2.39 (s, 3H, Pyr-CH₃).109 ^{13}C NMR (125 MHz, CDCl_3): δ ppm 171.5 (-COOH), 158.2 (-CONH), 148.9 (C5), 144.8 (ArCH=), 139.3, 139.1, 137.6, 131.2,110 129.2, 128.9, 128.7, 125.4, 120.5, 117.7 (C4), 109.1 (=CHCO), 13.7 (Pyr-CH₃). $R_f = 0.74$ (TLC: 2% HCOOH in EP/EtOAc 1:1);

111 whitish powder. M.p. = 108–110 °C. Yield: 202 mg (87%).

112

113




114

115 **Reagents and conditions:** LiOH 1 N, THF, 0°C-rt, 6h.

116

117 **20b:** (E)-3-(4-(5-methyl-1-phenyl-1H-pyrazole-3-carboxamido)phenyl)acrylic acid

118



119

120

121 Mol. Wt.: 347.37


122 ¹H NMR (500 MHz, Acetone-*d*₆): δ ppm 9.62 (bs, 1H, NH), 7.99 (d, 2H, *J* = 8.4 Hz, ArH), 7.67 (d, 2H, *J* = 8.4 Hz, ArH),123 7.65-7.54 (m, 6H, 5ArH + Ar-CH=), 6.78 (s, 1H, H-4), 6.47 (d, 1H, *J* = 15.9 Hz, =CHCO₂H), 2.41 (s, 3H, Pyr-CH₃).124 ¹³C NMR (125 MHz, Acetone-*d*₆): δ ppm 167.2 (-COOEt), 160.0 (-CONH), 146.7 (C3), 144.0 (ArCH=), 141.6, 139.5, 129.8,125 129.3, 128.9, 128.5, 127.0, 125.2, 119.7, 117.0 (C4), 107.3 (=CHCO), 11.5 (Pyr-CH₃). *R*_f = 0.41 (TLC: 2% HCOOH in

126 EP/EtOAc 1:1); whitish powder. M.p. = 143–147 °C. Yield: 123 mg (68%).

127

128 **Synthesis of the final hydroxamic acid with CAP N¹-phenyl-pyrazole (1a)**

129



130


131 **Reagents and conditions:** (1) TBDMSiO-NH₂ (1 eq), EDCI (1.5 eq), CH₂Cl₂, 0 °C to r.t., overnight; (2) TFA, CH₂Cl₂, 0 °C,

132 5h.

133

134 **1a:** (E)-N-(4-(3-(hydroxyamino)-3-oxoprop-1-enyl)phenyl)-3-methyl-1-phenyl-1H-pyrazole-5-carboxamide


135



136


137

138 Mol. Wt.: 362.38
 139 ^1H NMR (500 MHz, CD_3OD): δ ppm 7.63–7.40 (m, 10H, 9ArH + Ar-CH=), 6.79 (s, 1H, H-4), 6.40 (d, 1H, J = 15.9 Hz,
 140 =CHCONHOH), 2.36 (s, 3H, Pyr-CH₃).
 141 ^{13}C NMR (125 MHz, CD_3OD): δ ppm 165.0 (-CONHOH), 158.9 (-CONH), 149.1 (C5), 139.9 (ArCH=), 139.4, 137.9, 131.1,
 142 128.6, 128.0, 127.8, 126.1, 124.5, 120.2, 116.2 (C4), 108.6 (=CHCO), 13.2 (Pyr-CH₃). R_f = 0.51 (TLC: EtOAc/MeOH 8:2);
 143 yellowish powder. M.p. = 103–107 °C. Yield: 101 mg (48%). Anal. Calcd for $\text{C}_{20}\text{H}_{18}\text{N}_4\text{O}_3$: C, 66.29; H, 5.01; N, 15.46.
 144 Found: C, 66.35; H, 5.03; N, 15.50.
 145



146
 147 **Reagents and conditions:** (1) TBDMSiO-NH₂ (1 eq), EDCI (1.5 eq), CH_2Cl_2 , 0 °C to r.t., overnight; (2) TFA, CH_2Cl_2 , 0 °C,
 148 5h.


149
 150 **1b:** (E)-N-(4-(3-(Hydroxyamino)-3-oxoprop-1-enyl)phenyl)-5-methyl-1-phenyl-1H-pyrazole-3-carboxamide



151
 152
 153 Mol. Wt.: 362.38
 154 ^1H NMR (500 MHz, CD_3OD): δ ppm 7.81 (d, 2H, J = 8.4 Hz, ArH), 7.72 (d, 2H, J = 8.4 Hz, ArH), 7.65–7.54 (m, 5H, ArH),
 155 7.53 (d, 1H, J = 13.8 Hz, Ar-CH=), 6.80 (s, 1H, H-4), 6.30 (d, 1H, J = 13.8 Hz, =CHCONHOH), 2.36 (s, 3H, Pyr-CH₃).
 156 ^{13}C NMR (125 MHz, CD_3OD): δ ppm 165.2 (-CONHOH), 159.8 (-CONH), 148.1 (C3), 143.4 (ArCH=), 140.7, 139.6, 129.9,
 157 129.3, 129.1, 128.4, 126.8, 125.4, 118.8, 117.1 (C4), 107.5 (=CHCO), 11.9 (Pyr-CH₃). R_f = 0.18 (TLC: EtOAc/MeOH 8:2);
 158 yellowish powder. M.p. = 103–107 °C. Yield: 45 mg (42%). Anal. Calcd for $\text{C}_{20}\text{H}_{18}\text{N}_4\text{O}_3$: C, 66.29; H, 5.01; N, 15.46. Found:
 159 C, 66.26; H, 4.99; N, 15.49.
 160

161 *Synthesis of the other hydroxamic acids with CAP N¹-aryl-pyrazole (2-3)*


162



163

164 In regard to the other N¹-aryl-pyrazole derivatives (*i.e.* *p*-cyanophenyl **2** and *p*-bromophenyl **3**), the design and synthesis
 165 were carried out only on the related pyrazole scaffolds of the isomers **12a** and **13a**, respectively, in accordance with the
 166 preliminary biological data obtained with the N¹-phenyl analogs **1a,b**.

167

168 *Compound 2*169 **Ethyl 1-(4-cyanophenyl)-3-methyl-1H-pyrazole-5-carboxylate (12a)**


170

171

172 Mol. Wt.: 255.27

173 ¹H NMR (500 MHz, CDCl₃): δ ppm 7.71 (d, 2H, *J* = 8.8 Hz, H-2',6'), 7.55 (d, 2H, *J* = 8.8 Hz, H-3',5'), 6.85 (s, 1H, H-4), 4.25
 174 (q, 2H, *J* = 7.4 Hz, -CH₂CH₃), 2.34 (s, 3H, Pyr-CH₃), 1.28 (t, 3H, *J* = 7.4 Hz, -CH₂CH₃). R_f = 0.66 (TLC: EP/EtOAc 7:3). M.p.
 175 = 154–155 °C. White solid.

176

177 **1-(4-Cyanophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid (15a)**

178

179


180 Mol. Wt.: 227.22

181 ¹H NMR (500 MHz, Acetone-*d*₆): δ ppm 7.90 (d, 2H, *J* = 8.3 Hz, H-2',6'), 7.73 (d, 2H, *J* = 8.3 Hz, H-3',5'), 6.94 (s, 1H, Pyr-
 182 H-4), 2.31 (s, 3H, CH₃). White powder. R_f = 0.26 (TLC: 2% HCOOH in EP/EtOAc 1:1). M.p. = 225–226 °C.

183

184 **(E)-ethyl 3-(4-(1-(4-cyanophenyl)-3-methyl-1H-pyrazole-5-carboxamido)phenyl)acrylate (18a)**

185



186

187


188 Mol. Wt.: 400.43

189 ¹H NMR (500 MHz, CDCl₃): δ 8.58 (bs, 1H, NH), ppm 7.64 (d, 2H, *J* = 8.3 Hz, ArH), 7.60 – 7.55 (m, 5H, 4ArH + ArCH=),
190 7.44 (d, 2H, *J* = 8.8 Hz, Ar), 6.67 (s, 1H, Pyr-H-4), 6.34 (d, 1H, *J* = 15.7 Hz, =CHCO), 4.23 (q, 2H, *J* = 7.3 Hz, -CH₂CH₃), 2.31
191 (s, 3H, Pyr-CH₃), 1.31 (t, 3H, *J* = 7.3 Hz, -CH₂CH₃).

192 ¹³C NMR (125 MHz, CDCl₃): δ ppm 167.1 (-COOEt), 157.5 (-CONH), 150.1 (C5), 143.5 (ArCH=), 143.1, 138.9, 137.0, 132.6,
193 130.9, 128.9, 125.0, 120.1, 118.2 (-CN), 117.5 (C4), 111.0 (C-CN), 110.0 (=CHCO), 60.5 (CH₂), 14.2 (-CH₂CH₃), 13.3 (Pyr-
194 CH₃). White powder. *R*_f = 0.38 (TLC: EP/EtOAc 6:4). M.p. = 184–186 °C.

195

196 **(E)-3-(4-(1-(4-cyanophenyl)-3-methyl-1H-pyrazole-5-carboxamido)phenyl)acrylic acid (21a)**



197

198

199 Mol. Wt.: 372.38


200 ¹H NMR (500 MHz, Acetone-*d*₆): δ ppm 9.99 (bs, 1H, NH), 7.88 (d, 2H, *J* = 8.8 Hz, ArH), 7.81 (d, 2H, *J* = 8.3 Hz, ArH),
201 7.75 (d, 2H, *J* = 8.3 Hz, ArH), 7.68 (d, 2H, *J* = 8.8 Hz, ArH), 7.64 (d, 1H, *J* = 15.7 Hz, ArCH=), 6.93 (s, 1H, Pyr-H-4), 6.47
202 (d, 1H, *J* = 15.7 Hz, =CHCO), 2.32 (s, 3H, Pyr-CH₃).

203 ¹³C NMR (125 MHz, Acetone-*d*₆): δ ppm 173.9 (-COOH), 159.4 (-CONH), 149.1 (C5), 143.8 (ArCH=), 133.7, 132.6, 128.8,
204 128.3, 124.9, 120.21, (-CN), 116.7 (C4), 108.5 (C-CN), 103.3 (=CHCO), 13.3 (Pyr-CH₃). White powder. *R*_f = 0.43 (TLC: 2%
205 HCOOH in EP/EtOAc 6:4); M.p. = 248–250 °C.

206

207 **(E)-1-(4-cyanophenyl)-N-(4-(3-(hydroxyamino)-3-oxoprop-1-enyl)phenyl)-3-methyl-1H-pyrazole-5-carboxamide (2)**

208



209

210

211 Mol. Wt.: 387.39

212 ¹H NMR (500 MHz, CD₃OD): δ ppm 8.00–7.38 (m, 9H, 8ArH + Ar-CH=), 6.90 (s, 1H, H-4), 6.83 (d, 1H, *J* = 15.9 Hz,
213 =CHCONHOH), 2.35 (s, 3H, Pyr-CH₃).

214 ¹³C NMR (125 MHz, CD₃OD): δ ppm 164.9 (-CONHOH), 158.7 (-CONH), 150.3 (C5), 143.3 (ArCH=), 132.7, 129.2, 128.9,
215 128.1, 126.4, 124.9, 124.1 120.3 (-CN), 117.8 (C4), 115.1 (C-CN), 110.6 (=CHCO), 11.2 (Pyr-CH₃). Yellowish powder. *R*_f =
216 0.12 (TLC: EtOAc/MeOH 8:2); M.p. = 110–114 °C. Anal. Calcd for C₂₁H₁₇N₅O₃: C, 65.11; H, 4.42; N, 18.08. Found: C, 65.18;
217 H, 4.45; N, 18.13.


218

219 **Compound 3**

220

221 **Ethyl 1-(4-bromophenyl)-3-methyl-1H-pyrazole-5-carboxylate (13a)**

222



223


224

225 Mol. Wt.: 309.16

226 ¹H NMR (500 MHz, CDCl₃): δ ppm 7.56 (d, 2H, *J* = 8.8 Hz, H-3',5'), 7.39 (d, 2H, *J* = 8.8 Hz, H-2',6'), 6.81 (s, 1H, H-4), 4.24227 (q, 2H, *J* = 7.3 Hz, -CH₂CH₃), 2.35 (s, 3H, Pyr-CH₃), 1.26 (t, 3H, *J* = 7.3 Hz, -CH₂CH₃). *R*_f = 0.75 (TLC: EP/EE 7:3). Whitish

228 needles. M.p. = 137–138 °C.

229

230 **1-(4-Bromophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid (16a)**

231

232


233 Mol. Wt.: 281.11

234 ¹H NMR (300 MHz, CDCl₃): δ ppm 7.55 (d, 2H, *J* = 8.8 Hz, H-3',5'), 7.29 (d, 2H, *J* = 8.8 Hz, H-2',6'), 6.87 (s, 1H, H-4), 2.36235 (s, 3H, Pyr-CH₃). White solid. *R*_f = 0.29 (TLC: 2% HCOOH in EP/EtOAc 1:1); M.p. = 211–213 °C.

236

237 **(E)-Ethyl 3-(4-(1-(4-bromophenyl)-3-methyl-1H-pyrazole-5-carboxamido)phenyl)acrylate (19a)**

238



239

240


241 Mol. Wt.: 454.32

242 ¹H NMR (300 MHz, CDCl₃): δ ppm 7.87 (bs, 1H, NH), 7.61 (d, 2H, *J* = 8.4 Hz, ArH), 7.52 (d, 2H, *J* = 8.4 Hz, ArH), 7.46 (d,243 2H, *J* = 8.4 Hz, ArH), 7.42 (d, 1H, ArCH=), 7.31 (d, 2H, *J* = 8.4 Hz, ArH), 6.62 (s, 1H, Pyr-H-4), 6.35 (d, 1H, *J* = 15.7 Hz,244 =CHCO), 4.24 (q, 2H, *J* = 7.3 Hz, -CH₂CH₃), 2.34 (s, 3H, Pyr-CH₃), 1.32 (t, 3H, *J* = 7.3 Hz, -CH₂CH₃).245 ¹³C NMR (75 MHz, CDCl₃): δ ppm 168.6 (-COOEt), 159.5 (-CONH), 148.8 (C5), 144.2 (ArCH=), 141.1, 139.5, 137.7, 132.6,246 130.0, 128.9, 126.6, 121.3 (C-Br), 118.9, 117.1 (C4), 106.6 (=CHCO), 61.0 (CH₂), 13.4 (-CH₂CH₃), 12.3 (Pyr-CH₃). Whitish247 powder. *R*_f = 0.75 (TLC: EP/EtOAc 6:4); M.p. = 181–183 °C.

248

249 **(E)-3-(4-(1-(4-bromophenyl)-3-methyl-1H-pyrazole-5-carboxamido)phenyl)acrylic acid (22a)**

250



251

252


253 Mol. Wt.: 426.26

254 ^1H NMR (300 MHz, Acetone- d_6): δ ppm 9.96 (bs, 1H, NH), 7.90 (d, 2H, J = 8.3 Hz, ArH), 7.77–7.70 (m, 5H, 4ArH +
255 ArCH=), 7.56 (d, 2H, J = 8.3 Hz, ArH), 6.95 (s, 1H, Pyr-H-4), 6.54 (d, 1H, J = 15.7 Hz, =CHCO), 2.38 (s, 3H, Pyr-CH $_3$).256 ^{13}C NMR (75 MHz, CDCl $_3$): δ ppm 167.0 (-COOH), 158.0 (-CONH), 148.7 (C5), 144.1 (ArCH=), 140.8, 140.5, 137.8, 131.5,
257 130.0, 128.9, 126.5, 121.3 (C-Br), 120.0, 117.3 (C4), 109.5 (=CHCO), 12.6 (Pyr-CH $_3$). Whitish powder. R_f = 0.23 (TLC: 2%
258 HCOOH in EP/EtOAc 6:4); M.p. = 238–241 °C.

259

260 (E)-1-(4-Bromophenyl)-N-(4-(3-(hydroxyamino)-3-oxoprop-1-enyl)phenyl)-3-methyl-1H-pyrazole-5-carboxamide (3)

261



262

263


264 Mol. Wt.: 441.28

265 ^1H NMR (300 MHz, CD $_3$ OD): δ ppm 7.83 – 7.22 (m, 9H, 8ArH + Ar-CH=), 6.83 (s, 1H, H-4), 6.40 (d, 1H, J = 15.9 Hz,
266 =CHCONHOH), 2.35 (s, 3H, Pyr-CH $_3$).267 ^{13}C NMR (75 MHz, CDCl $_3$): δ ppm 166.1 (-CONHOH), 158.7 (-CONH), 148.9 (C5), 143.4 (ArCH=), 140.7, 139.7, 137.8,
268 131.6, 130.5, 128.7, 126.1, 122.0 (C-Br), 119.8, 117.0 (C4), 109.2 (-CHCO), 13.0 (Pyr-CH $_3$). R_f = 0.13 (TLC: EtOAc/MeOH
269 8:2); M.p. = 103–107 °C. Pale pink solid. Anal. Calcd for C $_{20}$ H $_{17}$ BrN $_4$ O $_3$: C, 54.44; H, 3.88; N, 12.70. Found: C, 54.52; H,
270 3.89; N, 12.73.

271

272 General procedure for the synthesis of N 1 H-pyrazole derivatives

273




274

275

276 **Scheme S2. Reagents and conditions** a) EtONa, EtOH, Δ , 4h; b) N $_2$ H $_4$, EtOH, Δ , 3h; c) LiOH 1N, EtOH, 0 °C to r.t., 5h;277 d) EDCl, HOBT, CH $_2$ Cl $_2$, 0 °C to r.t., overnight; e) LiOH 1N, EtOH, 0 °C to r.t., 6h; f) TBDMSiO-NH $_2$, EDCl, CH $_2$ Cl $_2$, 0278 °C to r.t., overnight; then TFA, CH $_2$ Cl $_2$, 0 °C, 5h.

279



280

281

282

283

284


285

286

287

Scheme S3. Reagents and conditions a) EtONa, EtOH, Δ , 4h; b) N_2H_4 , EtOH, Δ , 3h; c) HCl/ CH_3COOH_{glac} 1:1, overnight; d) EDCl, HOBT, CH_2Cl_2 , 0 $^\circ C$ to r.t., overnight; e) LiOH 1N, EtOH, 0 $^\circ C$ to r.t., 6h; f) TBDMSiO-NH₂, EDCl, CH_2Cl_2 , 0 $^\circ C$ to r.t., overnight; then TFA, CH_2Cl_2 , 0 $^\circ C$, 5h.

Synthesis of the α,γ -diketo-ester intermediate of the phenyl derivative



288


289

290

291

Reagents and conditions: EtONa, EtOH, Δ , 4h.

(Z)-Ethyl 4-hydroxy-2-oxo-4-phenylbut-3-enoate (26)



292

293

294

Mol. Wt.: 220.22

295


1H NMR (500 MHz, $CDCl_3$): δ ppm 7.98 (d, 2H, $J = 7.5$ Hz, PhH-2'-6'), 7.59 (t, 1H, $J = 7.5$ Hz, PhH-4'), 7.49 (t, 2H, $J = 7.5$ Hz, PhH-3'-5'), 7.07 (s, 1H, -CH=), 4.39 (q, 2H, $J = 7.1$ Hz, $-CH_2CH_3$), 1.40 (t, 3H, $J = 7.1$ Hz, $-CH_2CH_3$). $R_f = 0.76$ (TLC: CH_2Cl_2/CH_3OH 95:5). Dark brown sticky oil. Resa: 1.17 g (85%).

298

299

Synthesis of N^H -pyrazole scaffold C5-phenyl-substituted

300




301

302 Reagents and conditions: N_2H_4 , EtOH, Δ , 3h.

303

304 5-Phenyl-1H-pyrazole-3-carbohydrazide



305

306


307 Mol. Wt.: 202.21

308 ^1H NMR (500 MHz, $\text{DMSO}-d_6$): δ ppm 9.55 (bs, 1H, CONH-), 7.74 (d, 2H, $J = 7.4$ Hz, PhH-2'-6'), 7.43 (t, 2H, $J = 7.4$ Hz, PhH-3'-5'), 7.32 (t, 1H, $J = 7.4$ Hz, PhH-4'), 7.10 (s, 1H, PyrH-4), 4.44 (bs, 2H, -NH₂). $R_f = 0.10$ (TLC: 1% HCOOH in $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 95:5). Old rose powder; M.p. = 95–98 °C. Yield: 537 mg (50%).

310

311

312 (Z)-Ethyl 4-hydroxy-2-oxo-4-phenylbut-3-enoate (28)



314

315

316 Mol. Wt.: 216.24


317 ^1H NMR (500 MHz, CDCl_3): δ ppm 7.75 (d, 2H, $J = 7.9$ Hz, PhH-2'-6'), 7.42 (t, 2H, $J = 7.9$ Hz, PhH-3'-5'), 7.35 (t, 1H, $J = 7.9$ Hz, PhH-4'), 7.09 (s, 1H, PyrH), 4.36 (q, 2H, $J = 7.1$ Hz, -CH₂CH₃), 1.36 (t, 3H, $J = 7.1$ Hz, -CH₂CH₃). ^{13}C NMR (125 MHz, CDCl_3): δ ppm 160.5 (-COOEt), 149.4 (C5), 140.2 (C3), 130.7, 128.9, 128.6, 125.7, 105.5 (C4), 61.3 (CH₂), 14.2 (-CH₂CH₃). $R_f = 0.66$ (TLC: *n*-Hexane/EtOAc 7:3). Whitish solid; M.p. = 65–68 °C. Yield: 437 mg (38%).

320

321 *Hydrolysis of the N¹H-pyrazole scaffolds C5-phenyl-substituted*

322


323



324

325 **Reagents and conditions:** a) LiOH 1N, EtOH, 0 °C to r.t., 5h; b) HCl 6N/CH₃COOH_{gl.} (1:1), Δ, overnight.

326

327 **Ethyl 5-phenyl-1H-pyrazole-3-carboxylate (30)**

328

329


330 Mol. Wt.: 118.18

331 ¹H NMR (500 MHz, DMSO-*d*₆): δ ppm 13.78 (bs, 1H, PyrNH), 13.02 (bs, 1H, -COOH), 7.81 (d, 2H, *J* = 7.4 Hz, PhH-2'-6'),332 7.42 (t, 2H, *J* = 7.4 Hz, PhH-3',5'), 7.33 (t, 1H, *J* = 6.9 Hz, PhH-4'), 7.17 (s, 1H, PyrH-4). *R*_f = 0.13 (TLC: 1% HCOOH in333 CH₂Cl₂/CH₃OH 95:5). Whitish powder; M.p. = 119–121 °C. Yield route a: 350 mg (92%); yield route b: 426 mg (85%).

334

335 Coupling reaction between *N*¹H-5-phenyl-pyrazole scaffold (CAP) and cinnamoyl linker

336




337

338 Reagents and conditions: EDCI (1.5 eq), HOBT (1.5 eq), CH₂Cl₂, 0 °C to r.t., overnight.

339

340 (E)-Ethyl 3-(4-(5-phenyl-1H-pyrazole-3-carboxamido)phenyl)acrylate (32)



341

342


343 Mol. Wt.: 361.39

344 ¹H NMR (500 MHz, CDCl₃): δ ppm 8.99 (bs, 1H, -CONH), 7.76 (d, 2H, *J* = 8.8 Hz, ArH), 7.70 (d, 1H, *J* = 15.9 Hz, ArCH=),345 7.64 (d, 2H, *J* = 8.8 Hz, ArH), 7.54 (d, 2H, *J* = 8.4 Hz, ArH), 7.48 (t, 2H, *J* = 8.4 Hz, ArH), 7.43 (t, 1H, *J* = 8.4 Hz, ArH), 7.19346 (s, 1H, PyrH-4), 6.40 (d, 1H, *J* = 15.9 Hz, =CHCO), 4.27 (q, 2H, *J* = 7.0 Hz, -CH₂CH₃), 1.34 (t, 3H, *J* = 7.0 Hz, -CH₂CH₃).347 ¹³C NMR (125 MHz, CDCl₃): δ ppm 170.1 (-COOEt), 160.7 (-CONH), 148.2 (C3), 143.8 (ArCH=), 140.9 (C5), 138.7, 131.9,348 130.1, 129.4, 128.4, 125.6, 121.3, 118.1, 117.2 (=CHCO), 103.8 (C4), 61.2 (CH₂), 13.1 (-CH₂CH₃). *R*_f = 0.57 (TLC:349 CH₂Cl₂/EtOAc 8:2). Pale yellow powder; M.p. = 142–145 °C. Yield: 383 mg (57%).

350

351 Hydrolysis of the adduct *N*¹H-pyrazole CAP/cinnamoyl linker

352




353

354 Reagents and conditions: LiOH 1N, EtOH, 0 °C to r.t., 6h.

355

356 (E)-3-(4-(5-Phenyl-1H-pyrazole-3-carboxamido)phenyl)acrylic acid (34)



357

358


359 Mol. Wt.: 333.34

360 ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ ppm 13.83 (bs, 1H, PyrNH), 12.26 (bs, 1H, -COOH), 10.30 (bs, 1H, -CONH), 7.89 (d,
 361 2H, $J = 8.0$ Hz, ArH), 7.83 (d, 2H, $J = 7.5$ Hz, ArH), 7.66 (d, 2H, $J = 8.0$ Hz, ArH), 7.54 (d, 1H, $J = 15.9$ Hz, ArCH=), 7.47 (t,
 362 2H, $J = 7.5$ Hz, ArH), 7.37 (t, 1H, $J = 7.5$ Hz, ArH), 7.45 (s, 1H, PyrH-4), 6.44 (d, 1H, $J = 15.9$ Hz, =CHCO).

363 ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ ppm 168.2 (-COOH), 161.5 (-CONH), 148.1 (C3), 144.1 (ArCH=), 141.1 (C5), 138.8,
 364 131.7, 130.0, 129.5, 128.2, 125.8, 121.5, 118.2, 117.9 (=CHCO), 103.7 (C4). $R_f = 0.15$ (TLC: 2% HCOOH in $\text{CH}_2\text{Cl}_2/\text{MeOH}$
 365 95:5). Beige powder; M.p. = 171–174 °C. Yield: 219 mg (62%).

366
 367
 368


Synthesis of the final hydroxamic acid with CAP N¹H-5-phenyl-pyrazole (4)



369
 370
 371
 372
 373

Reagents and conditions: (1) TBDMSiO-NH₂ (1 eq), EDCI (1.5 eq), CH_2Cl_2 , 0 °C to r.t., overnight; (2) TFA, CH_2Cl_2 , 0 °C,
 5h.

(E)-N-(4-(3-(Hydroxyamino)-3-oxoprop-1-enyl)phenyl)-5-phenyl-1H-pyrazole-3-carboxamide (4)



374
 375
 376


Mol. Wt.: 348.36

377 ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ ppm 13.89 (bs, 1H, PyrNH), 9.64 (bs, 1H, -CONH), 7.84 (d, 2H, $J = 8.8$ Hz, ArH), 7.75
 378 (d, 2H, $J = 7.9$ Hz, ArH), 7.73 (d, 1H, $J = 16.1$ Hz, ArCH=), 7.64 (d, 2H, $J = 8.8$ Hz, ArH), 7.47 (t, 2H, $J = 7.9$ Hz, ArH), 7.38
 379 (t, 1H, $J = 7.9$ Hz, ArH), 7.20 (s, 1H, PyrH-4), 6.62 (d, 1H, $J = 16.1$ Hz, =CHCO).

380 ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ ppm 165.5 (-CONHOH), 161.0 (-CONH), 158.9 (ArCH=), 147.2 (C3), 141.1 (C5), 137.9,
 381 131.3, 130.0, 129.5, 129.0, 125.9, 120.9, (=CHCO), 103.7 (C4). $R_f = 0.14$ (TLC: 2% HCOOH in EtOAc/MeOH 8:2). Yellowish
 382 powder; M.p. = 254–258 °C. Yield: 87 mg (38%). Anal. Calcd for $\text{C}_{19}\text{H}_{16}\text{N}_4\text{O}_3$: C, 65.51; H, 4.63; N, 16.08. Found: C, 65.59;
 383 H, 4.60; N, 16.12.

384
 385
 386

Synthesis of the other hydroxamic acids with CAP N¹H-aryl-substituted-pyrazole (5-6)




387

388 In regard to this second group of derivatives, the other compounds, which were designed and synthesized with the
389 same procedure employed for the phenyl-derivative 4, are the *p*-bromophenyl (5) and the 1-indanone derivative (6),
390 whose experimental data of the various intermediates as well as of the final compounds are hereinafter reported.

391

392 *Compound 5*

393

394 **(Z)-Ethyl 4-(4-bromophenyl)-4-hydroxy-2-oxobut-3-enoate (27)**


395

396

397 Mol. Wt.: 299.12

398 ¹H NMR (500 MHz, CDCl₃): δ ppm 7.85 (d, 2H, *J* = 8.8 Hz, H-3',5'), 7.63 (d, 2H, *J* = 8.8 Hz, H-2',6'), 7.04 (s, 1H, -CH=),
399 4.38 (q, 2H, *J* = 7.4 Hz, -CH₂CH₃), 1.38 (t, 3H, *J* = 7.4 Hz, -CH₂CH₃). *R*_f = 0.82 (TLC: CH₂Cl₂/CH₃OH 95:5). Sticky reddish-
400 brown solid.

401

402 **Ethyl 5-(4-bromophenyl)-1H-pyrazole-3-carboxylate (29)**


403

404

405 Mol. Wt.: 295.13

406 ¹H NMR (500 MHz, CDCl₃): δ ppm 7.57 (d, 2H, *J* = 8.8 Hz, H-2',6'), 7.51 (d, 2H, *J* = 8.8 Hz, H-3',5'), 6.95 (s, 1H, PyrH-4),
407 4.24 (q, 2H, *J* = 6.9 Hz, -CH₂CH₃), 1.25 (t, 3H, *J* = 6.9 Hz, -CH₂CH₃). *R*_f = 0.35 (TLC: Hexane/EtOAc 7:3). Yellowish solid;
408 M.p. = 53–54 °C.

409

410 **5-(4-Bromophenyl)-1H-pyrazole-3-carboxylic acid (31)**


411

412

413 Mol. Wt.: 267.08

414 ¹H NMR (500 MHz, Acetone-*d*₆): δ ppm 7.86 (d, 2H, *J* = 8.0 Hz, H-2',6'), 7.62 (d, 2H, *J* = 8.0 Hz, H-3',5'), 7.27 (bs, 1H, -
415 COOH), 7.24 (s, 1H, PyrH-4). *R*_f = 0.12 (TLC: 1% HCOOH in CH₂Cl₂/CH₃OH 95:5). Beige powder; M.p. = 147–149 °C.

416

417 **(E)-Ethyl 3-(4-(5-(4-bromophenyl)-1H-pyrazole-3-carboxamido)phenyl)acrylate (33)**

418

419


420 Mol. Wt.: 440.29

421 ^1H NMR (500 MHz, DMSO- d_6): δ ppm 13.87 (bs, 1H, PyrNH), 10.31 (bs, 1H, -CONH), 7.90 (d, 2H, J = 8.4 Hz, ArH), 7.80
 422 (d, 2H, J = 8.3 Hz, ArH), 7.77-7.65 (m, 4H, ArH), 7.59 (d, 1H, J = 15.8 Hz, ArCH=), 7.26 (s, 1H, PyrH-4), 6.53 (d, 1H, J =
 423 15.8 Hz, =CHCO), 4.17 (q, 2H, J = 7.1 Hz, -CH₂CH₃), 1.24 (t, 3H, J = 7.1 Hz, -CH₂CH₃).

424 ^{13}C NMR (125 MHz, DMSO- d_6): δ ppm 170.3 (-COOEt), 165.1 (-CONH), 147.8 (C3), 143.8 (ArCH=), 140.9 (C5), 132.4,
 425 130.1, 129.4, 128.1, 125.1, 121.9 (C-Br), 120.7, 118.1, 106.2 (=CHCO), 104.0 (C4), 61.1 (CH₂), 13.2 (-CH₂CH₃). R_f = 0.65 (TLC:
 426 CH₂Cl₂/CH₃OH 95:5). Yellow powder; M.p. = 177–180 °C.

427

428 **(E)-3-(4-(5-(4-Bromophenyl)-1H-pyrazole-3-carboxamido)phenyl)acrylic acid (35)**



429

430


431 Mol. Wt.: 412.24

432 ^1H NMR (500 MHz, DMSO- d_6): δ ppm 10.53 (bs, 1H, -CONH), 7.91 (d, 2H, J = 8.8 Hz, ArH), 7.81 (d, 2H, J = 8.3 Hz, ArH),
 433 7.79 (d, 2H, J = 8.8 Hz, ArH), 7.65 (d, 2H, J = 8.3 Hz, ArH), 7.53 (d, 1H, J = 16.1 Hz, ArCH=), 7.22 (s, 1H, PyrH-4), 6.44 (d,
 434 1H, J = 16.1 Hz, =CHCO).

435 ^{13}C NMR (125 MHz, DMSO- d_6): δ ppm 168.2 (-COOH), 164.5 (-CONH), 147.9 (C3), 144.0 (ArCH=), 141.1 (C5), 132.3,
 436 129.9, 129.3, 127.8, 125.0, 121.8 (C-Br), 120.5, 118.0, 106.0 (=CHCO), 104.3 (C4). R_f = 0.20 (TLC: 2% HCOOH in
 437 CH₂Cl₂/CH₃OH 95:5). Beige powder; M.p. = 198–201 °C.

438

439 **(E)-5-(4-Bromophenyl)-N-(4-(3-(hydroxyamino)-3-oxoprop-1-enyl)phenyl)-1H-pyrazole-3-carboxamide (5)**



440

441 Mol. Wt.: 427.25

442 ^1H NMR (500 MHz, DMSO- d_6): δ ppm 10.56 (bs, 1H, -CONH), 7.89 (d, 2H, J = 8.8 Hz, ArH), 7.80 (d, 2H, J = 8.3 Hz, ArH),
 443 7.77 (d, 2H, J = 8.8 Hz, ArH), 7.64 (d, 2H, J = 8.3 Hz, ArH), 7.50 (d, 1H, J = 15.9 Hz, ArCH=), 7.19 (s, 1H, PyrH-4), 6.43 (d,
 444 1H, J = 15.9 Hz, =CHCO).

445 ^{13}C NMR (125 MHz, DMSO- d_6): δ ppm 168.4 (-CONHOH), 164.1 (-CONH), 148.0 (C3), 143.6 (ArCH=), 141.0 (C5), 132.1,
 446 129.8, 129.4, 128.0, 125.1, 121.7 (C-Br), 120.5, 118.1, 107.1 (=CHCO), 104.2 (C4). R_f = 0.17 (TLC: 2% HCOOH in
 447 EtOAc/CH₃OH 8:2). Beige powder; M.p. = 222–224 °C. %). Anal. Calcd for C₁₉H₁₅BrN₄O₃: C, 53.41; H, 3.54; N, 13.11.
 448 Found: C, 53.47; H, 3.51; N, 13.15.


449

450 **Compound 6**

451

452 **Ethyl 2-(3-hydroxy-1H-inden-2-yl)-2-oxoacetate (37)**

453




454

455

456 Mol. Wt.: 232.23

457 ¹H NMR (500 MHz, CDCl₃): δ ppm 7.87 (d, 1H, *J* = 7.9 Hz, PhH), 7.65 (t, 1H, *J* = 7.5 Hz, PhH), 7.55 (d, 1H, *J* = 7.9 Hz, PhH), 7.44 (t, 1H, *J* = 7.5 Hz, PhH), 4.42 (q, 2H, *J* = 7.1 Hz, -CH₂CH₃), 4.00 (s, 2H, Ind-CH₂), 1.43 (t, 3H, *J* = 7.1 Hz, -CH₂CH₃). R_f = 0.74 (TLC: CH₂Cl₂/CH₃OH 95:5). Sticky brownish solid.

460

461 **1,4-Dihydroindeno[1,2-*c*]pyrazole-3-carbohydrazide (38)**

462

463

464 Mol. Wt.: 214.22


465 ¹H NMR (500 MHz, DMSO-*d*₆): δ ppm 13.36 (bs, 1H, PyrNH), 9.91 (bs, 1H, CONH-), 9.35 (bs, 1H, CONH-), 7.61 (bs, 1H, PhH), 7.53 (d, 1H, *J* = 7.3 Hz, PhH), 7.34 (t, 1H, *J* = 7.3 Hz, PhH), 7.26 (t, 1H, *J* = 7.3 Hz, PhH), 4.59 (bs, 2H, -NH₂), 3.79 (bs, 2H, Ind-CH₂).

466 ¹³C NMR (125 MHz, DMSO-*d*₆): δ ppm 160.3 (-CONHNH₂), 148.2, 134.4, 127.5, 126.9, 126.7, 126.6, 126.0, 119.7, 110.0, 29.3 (CH₂). R_f = 0.11 (TLC: 2% HCOOH in CH₂Cl₂/CH₃OH 95:5). Brown powder; Mp >250 °C.

470

471 **1,4-Dihydroindeno[1,2-*c*]pyrazole-3-carboxylic acid (39)**

472



473

474

475 Mol. Wt.: 200.19


476 ¹H NMR (500 MHz, CD₃OD): δ ppm 7.82 (d, 1H, *J* = 8.4 Hz, PhH), 7.70 (d, 1H, *J* = 8.4 Hz, PhH), 7.49 (dt, 1H, *J*_o = 8.4 Hz and *J*_m = 0.8 Hz, PhH), 7.43 (dt, 1H, *J*_o = 8.4 Hz and *J*_m = 1.4 Hz, PhH), 2.88 (AB-system, 2H, *J* = 15.4 Hz, Ind-CH₂).

477 ¹³C NMR (125 MHz, DMSO-*d*₆): δ ppm 161.6 (-COOH), 148.4, 134.2, 127.6, 127.4, 127.0, 126.7, 119.7, 29.4 (CH₂). R_f = 0.26 (TLC: 2% HCOOH in CH₂Cl₂/CH₃OH 95:5). Dark orange powder; M.p. >250 °C.

480

481 **(*E*)-Ethyl 3-(4-(1,4-dihydroindeno[1,2-*c*]pyrazole-3-carboxamido)phenyl)acrylate (40)**

482



483

484

485 Mol. Wt.: 373.40


486 ¹H NMR (500 MHz, DMSO-*d*₆): δ ppm 13.74 (bs, 1H, PyrNH), 10.32 (bs, 1H, -CONH), 7.93 (d, 1H, *J* = 7.9 Hz, ArH), 7.76
 487 (d, 1H, *J* = 16.1 Hz, ArCH=), 7.68 (d, 2H, *J* = 8.8 Hz, ArH), 7.59 (2d, 3H, *J*₁ = 8.8 Hz and *J*₂ = 7.9 Hz, ArH), 7.38 (t, 1H, *J* =
 488 7.3 Hz, ArH), 7.30 (dt, 1H, *J*_o = 7.9 Hz and *J*_m = 1.0 Hz, ArH), 6.52 (d, 1H, *J* = 16.1 Hz, =CHCO), 4.16 (q, 2H, *J* = 7.4 Hz, -
 489 CH₂CH₃), 3.74 (s, 2H, Ind-CH₂), 1.24 (t, 3H, *J* = 7.4 Hz, -CH₂CH₃).

490 ¹³C NMR (125 MHz, DMSO-*d*₆): δ ppm 166.9 (-COOEt), 161.1 (-CONH), 151.0, 149.3, 144.5 (ArCH=), 141.5, 141.0, 131.6,
 491 130.6, 129.5, 127.4, 126.9, 120.3, 119.4, 116.7 (=CHCO), 60.3 (-CH₂CH₃), 29.7 (Ind-CH₂), 14.7 (CH₃). *R*_f = 0.58 (TLC:
 492 CH₂Cl₂/CH₃OH 95:5). Brownish powder; M.p. = 164–168 °C.

493

494 **(*E*)-3-(4-(1,4-Dihydroindeno[1,2-*c*]pyrazole-3-carboxamido)phenyl)acrylic acid (41)**

495



496

497


498 Mol. Wt.: 345.35

499 ¹H NMR (500 MHz, DMSO-*d*₆): δ ppm 13.77 (bs, 1H, PyrNH), 13.61 (bs, 1H, -COOH), 10.12 (bs, 1H, -CONH), 7.99 – 7.78
 500 (m, 1H, ArH), 7.65 (d, 2H, *J* = 8.7 Hz, ArH), 7.63 – 7.57 (m, 1H, ArH), 7.49 (d, 1H, *J* = 16.1 Hz, ArCH=), 7.37 (t, 1H, *J* = 7.8
 501 Hz, ArH), 7.35 (d, 2H, *J* = 8.7 Hz, ArH), 7.30 (t, 1H, *J* = 7.9 Hz, ArH), 6.43 (d, 1H, *J* = 16.1 Hz, =CHCO), 3.71 (s, 2H, Ind-
 502 CH₂).

503 ¹³C NMR (125 MHz, DMSO-*d*₆): δ ppm 168.2 (-COOH), 164.7 (-CONH), 154.8, 149.2, 144.1 (ArCH=), 141.6, 138.3, 130.8,
 504 129.8, 129.4, 127.4, 127.0, 120.4, 119.3, 117.7 (=CHCO), 29.4 (Ind-CH₂). *R*_f = 0.58 (TLC: 2% HCOOH in CH₂Cl₂/CH₃OH
 505 95:5). Rusty powder; M.p. >250 °C.

506

507 **(*E*)-*N*-(4-(3-(hydroxyamino)-3-oxoprop-1-enyl)phenyl)-1,4-dihydroindeno[1,2-*c*]pyrazole-3-carboxamide (6)**



508

509 Mol. Wt.: 360.37

510 ¹H NMR (500 MHz, DMSO-*d*₆): δ ppm 13.88 (bs, 1H, PyrNH), 9.98 (bs, 1H, -CONH), 8.00 – 7.80 (m, 1H, ArH), 7.67 (d,
 511 2H, *J* = 8.8 Hz, ArH), 7.65 – 7.53 (m, 1H, ArH), 7.50 (d, 1H, *J* = 16.1 Hz, ArCH=), 7.36 (t, 1H, *J* = 7.9 Hz, ArH), 7.32 (d, 2H,
 512 *J* = 8.8 Hz, ArH), 7.29 (t, 1H, *J* = 7.9 Hz, ArH), 6.40 (d, 1H, *J* = 16.1 Hz, =CHCO), 3.69 (s, 2H, Ind-CH₂).

513 ¹³C NMR (125 MHz, DMSO-*d*₆): δ ppm 169.5 (-CONHOH), 165.1 (-CONH), 155.0, 149.1, 143.9 (ArCH=), 141.5, 138.5,
 514 130.8, 129.9, 129.4, 127.2, 126.9, 120.6, 119.4, 117.8 (=CHCO), 29.6 (Ind-CH₂). *R*_f = 0.58 (TLC: 2% HCOOH in
 515 EtOAc/CH₃OH 8:2). Rusty powder; M.p. >250 °C. Anal. Calcd for C₂₀H₁₆N₄O₃: C, 66.66; H, 4.48; N, 15.55. Found: C,
 516 66.70; H, 4.46; N, 15.58.